Arterial hypertension is the main predisposing factor for the risk of cardiovascular events (heart attacks and strokes) in the Western world.

However, despite the advances in modern pharmacology, approximately 12-18% of hypertensive patients suffer from resistant hypertension, that is, they do not respond to drug therapy, even with the use of at least three antihypertensive drugs.

In the last 10 years, methods have been developed to treat these patients through renal aponeurosis, which destroys part of the renal plexus around the renal arteries. This plexus is considered responsible for triggering neural reflex mechanisms that contribute to the increase in blood pressure. Initial efforts to treat patients with resistant hypertension have been encouraging, while this method is also being tested in patients with heart failure and atrial fibrillation.

Patients who can benefit from invasive treatment are those who have arterial hypertension resistant to taking at least three drugs or those who cannot follow the indicated medication due to side effects.

Recently new studies have confirmed the usefulness and safety of the method with satisfactory long-term results and in a recent publication the European Society of Cardiology recommends the operation in patients with resistant hypertension [Renal  denervation  in  the  management of hypertension in adults. A clinical consensus statement of the ESC Council on  Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). EurHeartJ. 2023].

The team of the 3rd Cardiology Clinic of HYGEIA has long experience in performing renal aponeurosis. They were one of the first groups to perform these operations in Greece and continue to apply this method with success.